Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice

Table 3 Cytogenetics

Cytogenetics^a	IRD (N = 127)	RD (N = 217)	p¹
t(4;14), n (%)	n = 59	n = 86
Negative	53 (89.8%)	80 (93.0%)	0.548
Positive	6 (10.2%)	6 (7.0%)	0.548
t(14;16), n (%)	n = 52	n = 69
Negative	49 (94.2%)	66 (95.7%)	1.000
Positive	3 (5.8%)	3 (4.3%)	1.000
del(17p13), n (%)	n = 66	n = 91
Negative	58 (87.9%)	79 (86.8%)	1.000
Positive	8 (12.1%)	12 (13.2%)	1.000
Cytogenetics - risk groups^b, n (%)	n = 54	n = 77
Standard risk	39 (72.2%)	58 (75.3%)	0.691
High risk	15 (27.8%)	19 (24.7%)	0.691

^a Only cytogenetics evaluated at diagnosis before treatment initiation included. Cytogenetics assessed in 69% of IRD patients (87/127) and 49% of RD patients (106/217) but most patients did not have all required parameters assessed. The table contains only the three major risk aberrations
^b “standard risk” = negative t(4;14) and t(14;16) and del(17p13); “high risk” = positive at least one of these aberrations
¹ p-value of Fisher’s exact test for categorical variables

ISSN: 1471-2407